Manual on meat inspection for developing countries

'Poop Pills' Tested In Pancreatic Cancer Patients

A research team at Canada's Lawson Research Institute of St. Joseph's Health Care London and the London Health Sciences Center Research Institute (LHSCRI) is readying a two-year Phase I safety trial in which a small group of cancer patients will receive fecal microbiota transplantation (FMT)—aka "poop pills." Although the less-than-appetizing supplements are still in their early stages of development, the innovative approach has already shown promise in boosting recovery chances for other forms of cancer like melanoma.

Pancreatic cancer remains difficult to treat, and is responsible for around 8 percent of all cancer deaths.It also has one of the lower longterm survival rates with only about 13 percent of patients surviving more than five years. Part of this is due to the ecosystems surrounding cancerous tumors, which possess their own microbial communities that include fungi, viruses, and bacteria. These systems can make certain cancers more resistant to chemotherapy regimens. In recent years, researchers began wondering if altering these microbial populations could make tumors more receptive to existing treatment options.

Fecal transplants as a medical tool aren't new. In fact, increasing evidence suggests poop-based medications may improve people's resilence against superbugs and other dangerous health problems. Since the FDA's approval of the first fecal transplant pills in 2023, many experts are hopeful that adapting it and similar innovations could help treat particularly resistant cancers.

Fecal microbiota transplantation isn't nearly as gross as it sounds. First, stool samples are collected from prescreened health donors before being processed in a lab. During the standard procedure, the stool is filtered for its helpful bacterial contents while the remaining material is discarded. The resulting odorless and tasteless solution is packed into LND101 capsules, The pancreatic cancer patients will take the pills on a specific dosage calendar. From there, experts will study how the gut biomes of trial volunteers change over time, and how that may affect their overall immune systems while battling cancer.

Get the Popular Science newsletter

Breakthroughs, discoveries, and DIY tips sent every weekday.

By signing up you agree to our Terms of Service and Privacy Policy.

"Our goal is to determine whether a successful shift in the gut microbiome is connected to a better response to chemotherapy," study co-lead Saman Maleki said in St. Joseph's Health Care London profile on February 26.

According to trial collaborator Seema Nair Parvathy, earlier studies indicate fecal microbiota transplantation has helped improve outcomes for patients with advanced lung, renal cell, and skin cancers. But the team stressed their clinical studies are only possible through the help of poop donors. As they enter trials, researchers are seeking volunteers between the ages of 18 and 50 who haven't taken antibiotics in at least six months, are not immunocompromised, and do not have chronic gastrointestinal disorders.

  More deals, reviews, and buying guides The PopSci team has tested hundreds of products and spent thousands of hours trying to find the best gear and gadgets you can buy.  

First Pill For Fecal Transplants Wins FDA Approval

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

Immune System-gut Bacteria Interactions Altered In MS: Study

Interactions between the body's immune system and bacteria that live in the digestive tract — essentially, a person's gut — become disrupted in multiple sclerosis (MS), a new study by U.S. Researchers found.

The human intestines are home to billions of bacteria and other microorganisms, collectively known as the gut microbiome. These bacteria normally play important roles in health, including the regulation of the body's immune responses.

However, new research by scientists at Yale University School of Medicine and the Mayo Clinic found alterations in these interactions in the gut in people with MS. The team also discovered that certain immune-modulating MS treatments may affect these relationships.

According to the researchers, the findings highlight "shifts in gut microbial [types] induced by immune [changes] in MS, suggesting the potential for leveraging these changes as biomarkers or therapeutic targets."

Their study, "Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis," was published in the journal Neurology Neuroimmunology and Neuroinflammation.

Scientists used stool samples from patients, controls to analyze gut microbiome

Studies have previously shown that the gut microbiome becomes dysregulated in MS, but there hasn't been much investigation specifically into how the interaction between gut bacteria and the immune system is affected.

"Although gut microbiome [disruption] is now recognized in MS, the interactions between the gut microbiome and the host's immune response to this disease remain largely unexplored," the researchers wrote.

Now, the team of researchers specifically looked at how MS affects the number of gut bacteria that are coated with immunoglobulin A (IgA) antibodies.

Antibodies are proteins made by the immune system to help combat potential threats. Immune cells in mucus-coated organs, including the intestines, release a specific type of antibody called IgA that binds to certain types of gut bacteria, limiting their movement and/or leading to their death.

The study included 43 people with newly diagnosed, untreated MS, as well as 42 age- and sex-matched healthy people, who served as controls. Stool samples were collected from all participants to analyze the gut microbiome and the proportion of IgA-coated bacteria.

The results showed significant differences in the types of bacteria making up the gut microbiome between individuals with or without MS, which is generally consistent with previous reports.

[These findings suggest] that there is perhaps a fundamental disconnect going on with the host-microbe interactions [in the gut microbiome in MS].

Further, the MS patients had significantly fewer bacteria coated with the IgA antibodies, as noted by Erin Longbrake, MD, PhD, the study's cosenior author and an associate professor of neurology at the Yale School of Medicine.

That "suggests that there is perhaps a fundamental disconnect going on with the host-microbe interactions," Longbrake said in a university news story.

Significant differences found in specific gut bacteria after MS treatment

After the initial analyses, 19 of the MS patients (44%) started treatment with CD20 inhibitors. This type of MS treatment works to deplete B-cells, the immune cells that are responsible for making antibodies.

After a few months of such treatment, new stool samples from these patients were collected by the researchers, who sought to determine how the use of CD20 inhibitors was affecting IgA coating in the gut microbiome.

The team found that the proportion of bacteria that were coated with IgA was not affected by CD20 inhibitors. However, when the researchers looked at the results in more detail, they found that there were significant differences in specific bacteria types.

The analysis "identified specific organisms where IgA-coating patterns were lost following B-cell-depleting therapy, as well as organisms whose IgA-coating patterns shifted to align more closely with controls," the researchers wrote.

According to the team, this "work illustrates that the host response to the gut microbiome, including relationships between [IgA-coated] and total gut bacteria, is dysregulated in early-stage MS, building on previous work where decreased proportions of [IgA-coated] gut bacteria were associated with high levels of physical disability and recent clinical relapses."

These findings mean that such MS-related changes have the potential to be used as markers of disease activity or targets of new treatments, the researchers noted. However, per the team, further analyses of IgA-gut bacteria interactions over time in MS are needed to further inform the potential utility of these results.

"We're still analyzing what our results mean and how we can use this information to improve care," Longbrake said. "These are areas to investigate in the future."

The researchers' work was supported by several awards from the National Institutes of Health.

---